Cardiogen is a synthetic short peptide from the Khavinson “bioregulator” family, marketed for cardiac and cardiovascular-tissue support. Vendor sources disagree sharply on its exact sequence, and no PubMed-indexed study specifically confirming a compound named “Cardiogen” was identified in this review — the closest related published work concerns differently named tripeptides (AED and EDL) studied in kidney rather than heart tissue. It is also frequently confused online with a distinct product called “Cardiogen-3.” It is not an approved drug anywhere.
Research snapshot
| Peptide category | Khavinson-family short “bioregulator” peptide, marketed for cardiac/cardiovascular-tissue support |
| Primary research interest | Cardiac and cardiovascular tissue support (marketed; not independently confirmed) |
| Highest available evidence | Tier 4 — the closest related published work concerns differently named tripeptides (AED and EDL) studied in kidney cell culture, not heart tissue, and not confirmed to be the same compound sold as “Cardiogen” |
| Human research available | No — no human clinical trial of Cardiogen was located, and no primate or human cardiac data exists even in sources favorable to the concept |
| Development status | Not in formal pharmaceutical development; sold as an oral “bioregulator” supplement/research chemical |
| Regulatory status | No drug approval identified in the United States, European Union, or Russia; has not entered any recognized clinical trial |
| Last reviewed | September 2026 |
Technical identity
| Primary name | Cardiogen |
| Alternative names | Frequently confused online with a distinct product called “Cardiogen-3” |
| Peptide sequence | Not reliably established — vendor sources disagree sharply on its exact sequence, and no PubMed-indexed study specifically confirming a compound named “Cardiogen” was identified |
| Amino-acid length | Not reliably established |
| Molecular formula | Not independently verified in this pass |
| Molecular weight | Not independently verified in this pass |
| CAS Registry Number | Not reliably established |
| PubChem CID | Not reliably established |
| Peptide class | Khavinson-group “bioregulator” peptide line (Saint Petersburg Institute of Bioregulation and Gerontology) |
| Primary biological target | Not established — closest related published research (AED/EDL tripeptides) concerns kidney rather than heart tissue |
| Developer or originator | Saint Petersburg Institute of Bioregulation and Gerontology (Khavinson group), for the broader bioregulator line |
| Development status | Not an approved or registered pharmaceutical anywhere identified in this review |
What it is
Cardiogen is marketed as part of the Khavinson-group bioregulator peptide line developed at the Saint Petersburg Institute of Bioregulation and Gerontology, positioned as the cardiovascular-system entry in the family alongside Vesugen (vascular), Vilon (immune), and others. Vendor educational content acknowledges that published research relevant to it is “almost exclusively from the Khavinson group,” that there is “no primate or human cardiac data,” and that “no human clinical trials (Phase I, II, or III) for defined Cardiogen have been conducted.”
Important sourcing conflict: one detailed vendor educational source describes Cardiogen’s sequence as a tetrapeptide “AEDR.” This is not the same sequence given in the task-level research briefing used to develop this entry (Ala-Glu-Asp-Leu, “AEDL”), and neither AEDR nor AEDL is the sequence that actually appears in the PubMed-indexed literature reviewed for this entry, which instead describes a tripeptide “EDL” (Glu-Asp-Leu) studied alongside AED in aging kidney cell culture — not a cardiac tissue study, and not clearly the same compound marketed as “Cardiogen.” Separately, “Cardiogen” is sometimes confused with “Cardiogen-3,” a distinctly named product in vendor catalogs; this review could not confirm whether Cardiogen-3 is the same compound under a different name, a reformulation, or an entirely separate peptide, and treats the two as unresolved and distinct pending further verification. Readers should regard every claimed sequence for “Cardiogen” as unverified.
How does it work?
Plain-English explanation
The general theory behind this peptide family is that very short peptides can nudge aging cells in a specific organ toward more youthful gene activity. For Cardiogen, this idea has not been directly tested and confirmed in a peer-reviewed, heart-tissue-specific study identified under this compound’s name in this review.
Technical explanation
The closest related PubMed-indexed finding located in this review involves the tripeptide EDL (Glu-Asp-Leu), studied together with AED (Ala-Glu-Asp) in an aging renal (kidney) cell-culture model, where both peptides reportedly increased cell proliferation, decreased expression of senescence markers p16, p21, and p53, and increased sirtuin-6 expression, with proposed DNA-binding interactions in the minor groove of AT-rich sequences (Khavinson et al., 2014, Adv Gerontol, PMID 25946838). This study used kidney cells, not cardiac tissue, and its EDL sequence does not match either “AEDR” or “AEDL,” the two sequences seen attributed to Cardiogen across different sourcing in this review. No cardiac-tissue-specific mechanistic data attributable to a confirmed “Cardiogen” compound were identified.
Potential benefits and research applications
Cardiac and cardiovascular tissue support (as marketed)
What is being investigated: vendor marketing describes Cardiogen as supporting cardiac cellular aging, heart tissue maintenance, and cardiovascular gene regulation. How the effect might occur: not established by any cardiac-tissue-specific study identified in this review. Evidence: none identified specific to confirmed heart tissue or cardiomyocyte research under this compound name. Strength: has not been established. Even sources favorable to the Khavinson bioregulator concept describe this application as extrapolated rather than directly demonstrated, with an explicit acknowledgment of no primate or human cardiac data and no completed human trials.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
Amounts studied in human research
No established or reliably sourced dosing information was identified. No human clinical trial of Cardiogen was located.
Amounts studied in animal research
No established or reliably sourced dosing information specific to a confirmed “Cardiogen” compound was identified. The related published kidney-cell study (EDL/AED) was an in vitro cell-culture experiment, not a whole-animal dosing study, so it provides no animal amount, frequency, or route to report here. Not consistently reported.
Practitioner and community-reported protocols
Vendors selling Cardiogen as an oral capsule or 20 mg reconstituted vial commonly describe roughly 10-20 mg per day for a 10-20 day course, matching the generic Khavinson-line “bioregulator” template applied across this entire peptide family, without a compound-specific citation. This is widely repeated online, but its original source could not be verified.
Explanation of the reported figures
Cardiogen is a case where even the peptide’s identity is unsettled: the sequence attributed to it varies by source (AEDR per one vendor source, AEDL per the research brief behind this entry, and neither matching the EDL tripeptide that actually appears in PubMed-indexed Khavinson-group work). Because the compound cannot be confidently matched to a specific published study, no dosing figure in this section can be traced to a verifiable source. The commonly repeated oral capsule figure (10-20 mg over 10-20 days) is a template shared across many unrelated peptides in this product family and should not be read as evidence specific to cardiac research.
What circulates E5
Vendors selling Cardiogen as an oral capsule or 20 mg reconstituted vial commonly describe roughly 10-20 mg per day for a 10-20 day course, matching the generic Khavinson-line "bioregulator" course template used across this whole peptide family, without a compound-specific citation. Widely repeated online, but its original source could not be verified. Given the unresolved conflicts over the compound's actual identity and sequence described above, no dosing figure for "Cardiogen" specifically can be traced to a verifiable published source, human or animal. Treat any specific "X mg/day" figure for Cardiogen as community/vendor-tier information only.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Side effects, risks, and limitations
No human or confirmed animal cardiac study exists to characterize side effects for this compound. As with other unregulated peptide products, purity, accurate labeling, contamination, correct concentration, and sterility are not guaranteed for vendor-sold Cardiogen. Given the unresolved identity of the compound itself, essentially nothing about its safety, mechanism, or appropriate dose has been independently established.
Regulatory and developmental status
Cardiogen has no drug approval in the United States, European Union, or Russia identified in this review. It is sold as an oral “bioregulator” supplement and research chemical, not as a registered pharmaceutical, and has not entered any recognized clinical trial pipeline identified in this review. Status verified as of the date below.
Frequently asked questions
What is Cardiogen?
A marketed Khavinson-family “bioregulator” peptide positioned for cardiac/cardiovascular support. Its exact sequence could not be confirmed, and it is inconsistently described across sources.
What is the sequence of Cardiogen?
Not reliably established. Sources disagree: one vendor gives “AEDR” (Ala-Glu-Asp-Arg), an earlier research brief referenced “AEDL” (Ala-Glu-Asp-Leu), and the closest matching PubMed-indexed study instead describes a different tripeptide, “EDL” (Glu-Asp-Leu), studied in kidney rather than heart tissue. None of these were independently confirmed as the definitive Cardiogen sequence in this review.
Is Cardiogen the same as Cardiogen-3?
This could not be confirmed. The two names appear separately in vendor catalogs, and this review found no authoritative source clarifying whether they are the same compound, a reformulation, or distinct peptides. Treat them as unresolved and distinct until verified.
Has Cardiogen been studied in humans?
No. Multiple sources, including vendor educational material, explicitly state that no human or primate cardiac data and no completed human trials exist for Cardiogen.
What dosage circulates online?
Vendors commonly describe roughly 10-20 mg oral courses over 10-20 days, but this figure is widely repeated without an identifiable original clinical or animal source, and cannot be confidently tied to a specific verified compound given the sequence conflicts above.
Is Cardiogen approved anywhere?
No. It is not an approved medicine in any jurisdiction identified in this review.
What remains unknown?
Essentially everything: the compound’s actual confirmed sequence, whether it has ever been tested in cardiac tissue specifically, its relationship (if any) to “Cardiogen-3,” and any verifiable human or animal dosing figure.
Bottom line
Cardiogen is one of the most poorly documented and internally inconsistent entries in the Khavinson bioregulator family: its sequence is reported differently across sources, it has no confirmed PubMed-indexed study under its own name, the closest related published work used a different tripeptide in kidney (not heart) tissue, and even its relationship to the separately marketed “Cardiogen-3” is unclear. No human or confirmed animal cardiac data exist. It should be treated as a marketed research/supplement product whose identity and evidence base remain substantially unverified, not as a studied cardiovascular therapeutic.